Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib + Palbociclib + Faslodex in Neoadjuvant ER+/HER2- Breast Cancer
NCT02626507Phase 1Unknown
- Start
- Jan 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gedatolisib in breast cancer. Primary endpoint: Treatment-related adverse events. Status: unknown.
02
Drugs
gedatolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02626507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626507.